...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.
【24h】

Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.

机译:慢性GVHD风险评分:国际血液和骨髓移植研究中心的分析。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Several risk factors are associated with increased mortality in patients with chronic graft-versus-host disease (cGVHD), but there is considerable variability in the reported factors. Therefore, we evaluated patient, transplantation, and cGVHD characteristics to develop a risk score in 5343 patients with cGVHD. Ten variables were identified as being significant in multivariate analysis of overall survival and nonrelapse mortality (NRM): age, prior acute GVHD, time from transplantation to cGVHD, donor type, disease status at transplantation, GVHD prophylaxis, gender mismatch, serum bilirubin, Karnofsky score, and platelet count. These 10 variables were used to build a cGVHD risk score, and 6 risk groups (RGs) were identified. The 5-year NRM was 5% (1%-9%) in RG1, 20% (19%-23%) in RG2, 33% (29%-37%) in RG3, 43% (40%-46%) in RG4, 63% (53%-74%) in RG5, and 72% (59%-85%) in RG6. The 5-year overall survival was highest at 91% (95% confidence interval [CI]:85%-97%) in RG1, followed by 67% (65%-69%) in RG2, 51% (46%-55%) in RG3, 40% (37%-43%) in RG4, 21% (12%-30%) in RG5, and 4% (0%-9%) in RG6 (all P < .01). This analysis demonstrates the usefulness of data from a large registry to develop risk-score categories for major transplantation outcomes. Validation of this cGVHD risk score is needed in a different population to ensure its broad applicability.
机译:慢性移植物抗宿主病(cGVHD)患者的死亡率增加与一些危险因素有关,但报告的因素存在很大差异。因此,我们评估了患者,移植和cGVHD的特征,以对5343名cGVHD患者进行风险评分。在总体生存和非复发死亡率(NRM)的多变量分析中,十个变量被认为是重要的:年龄,急性急性GVHD,从移植到cGVHD的时间,供体类型,移植时的疾病状态,GVHD预防,性别失配,血清胆红素,卡诺夫斯基分数和血小板计数。这10个变量用于建立cGVHD风险评分,并确定了6个风险组(RGs)。五年期NRM在RG1中为5%(1%-9%),在RG2中为20%(19%-23%),在RG3中为33%(29%-37%),43%(40%-46%) )在RG4中占63%(53%-74%),在RG6中占72%(59%-85%)。 5年总生存率最高的是RG1,为91%(95%置信区间[CI]:85%-97%),其次是RG2,为67%(65%-69%),其次是51%(46%-55) RG3中的百分比),RG4中的40%(37%-43%),RG5中的21%(12%-30%)和RG6中的4%(0%-9%)(所有P <0.01)。这项分析表明,来自大型注册机构的数据对于制定主要移植结果的风险评分类别非常有用。需要在不同人群中验证此cGVHD风险评分,以确保其广泛的适用性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号